Bone density evaluation for patients with prostate cancer and receiving androgen deprivation therapy

Last updated: May 3, 2018

CMS Measure ID: CMS645v1
Version: 1
NQF Number: None
Measure Description:

Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.

Initial Patient Population:

Male patients with a diagnosis of prostate cancer and an order for or who are actively undergoing ADT for a period greater than or equal to 12 months with an office visit during the measurement period

Denominator Statement:

Equals Initial Populationinfo-icon

Denominator Exclusions:

None

Numerator Statement:

Patients with a bone density evaluation within the two years prior to the start of or less than three months after the start of ADT treatment

Numerator Exclusions:

None

Denominator Exceptions:

Patient refused recommendation for a bone density evaluation after the start of ADT therapy

Measure Steward: Oregon Urology
Domain: Effective Clinical Care
Next Version:
Improvement Notation:

A higher score indicates better quality

Guidance:

In order to capture the practitioner's intent of androgen deprivation therapy (ADT) for a period of 12 months or greater, the custom HCPCS code of J1950,cont was added to the $ADT variable as Procedure, Order. Each EHRinfo-icon can define this custom code as intended therapy for 12 months or greater with the practitioner indicating this code at the start of the intended therapy.

Notes: Not available for Medicaid EHR Incentive Program for Eligible Professionals

Specifications

External Resources